BioSpace News Archive

Company Appoints Kimberly Vanover, Ph.D. as Chief Scientific Officer and Eve Taylor, Ph.D. as Vice President, Clinical Development - Tony Ho, M.D. Joins Board as Independent Director

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in several upcoming investor conferences. AtriCure will be participating in the Guggenheim MedTech Disruptors Summit, scheduled to be held virtually August 10-11, 2020. AtriCure’s management is scheduled to present

PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar second quarter 2020 financial results by press release on Thursday, August 6, 2020 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on Thursday, August 6, 2020 at 8:00 a.m. Eastern Time. The conference call can be accessed by calling 1-888-599-8688 (U.S. and Canada) or +4

ORTIKOS ™ (budesonide), the First and Only Once-Daily Dose for Treatment of Mild to Moderate Crohn’s Disease, Now Available in the U.S. ORTIKOS is available in one convenient pill in two dosage strengths (9mg, 6mg) for the treatment of mild to moderate active Crohn’s disease in patients 8 years and older and maintenance of clinical remission for up to three months in adults 1 Approximately 800,000 Americans are currently living with Crohn’s

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2020 financial results after the Nasdaq Global Market closes on Wednesday, August 5, 2020. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2020 financial results and to provide a corporate update. The conference call may be accessed by dialing (844) 534-7313 f

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today it had completed over 180,000 Cancer Differentiation Analysis (“CDA”) based tests as of July 15, 2020. AnPac Bio had previously completed more than 169,000 CDA-based tests as of March 31, 2020. From April 1, 2020 to Jul

Sonendo®, Inc., a leading dental technology company and developer of the GentleWave® System, announced that the GentleWave System creates virtually no aerosols during root canal treatment.

Vineti, the California -based company that offers a digital platform to enable broad access to advanced therapeutics, and EVERSANA™, a provider of global integrated commer

Sekisui announces the decision to invest £14.4 Million in its biopharma CDMO business aimed at cGMP microbial capacity expansion at the existing site in Maidstone, Kent to be completed by the second half of 2022. This investment follows the investment of $1.9 million in its new Bioprocess Innovation Centre, completed in Octobe

The Pancreatic Cancer Action Network (PanCAN) and GeneCentric Therapeutics, Inc. today announced that they have entered into a collaborative research partnership for the advancement of RNA-based molecular signatures for pancreatic c